Myeloma

On February 23, 2024, Legend Biotech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval for the expanded indication of Carvykti (cilta-cel, ciltacabtagene autoleucel) to include the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy, including an immunomodulatory agent and a proteasome inhibitor.

Carvykti is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of relapsed or refractory multiple myeloma (R/R MM).

In the near future, CAR-T cell therapy products for multiple myeloma will gradually be launched in China and soon enter clinical practice, which is good news. However, we still face many pressing real-world issues that need to be addressed.

BCMA CAR-T cell therapy is an innovative approach for the treatment of multiple myeloma. In a recent “Blood Spotlight” article published in Blood, the authors reviewed relevant clinical and preclinical data supporting the incorporation of CAR-T cells into frontline therapy and their use prior to T-cell engager antibodies.

According to the data from Cohort B of the phase 2 CARTITUDE-2 trial presented at the 2022 EHA Annual Meeting, the CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti) demonstrated a very high response rate in patients with early relapsed or primary refractory multiple myeloma.
In

On March 5, 2024, China’s fifth CAR-T cell therapy, Zevorcabtagene Autoleucel(trade name: Sai Kaize), developed by Keymed Biosciences.

Professor Jin Jie’s team from the Department of Hematology at the First Affiliated Hospital of Zhejiang University School of Medicine applied the CAR-T cell therapy Zevorcabtagene Autoleucel (CT053) to treat a high-risk multiple myeloma patient who experienced early relapse after anti-CD38 monoclonal antibody treatment.

On March 1, 2024, CARsgen Therapeutics announced that its CAR-T product candidate Zevorcabtagene Autoleucel (CT053) has received formal approval from the National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory multiple myeloma.